4.4 Article

Minimizing Shivering During Targeted Normothermia: Comparison Between Novel Transnasal and Surface Temperature-Modulating Devices

Related references

Note: Only part of the references are listed.
Article Critical Care Medicine

Safety and Feasibility of a Novel Transnasal Cooling Device to Induce Normothermia in Febrile Cerebrovascular Patients

Neeraj Badjatia et al.

Summary: This study tested the safety and feasibility of a novel transnasal evaporative cooling device for inducing and maintaining normothermia in febrile stroke patients. Results showed 90% of patients achieved normothermia without significant adverse events or shivering. A multicenter trial testing the device's ability to maintain normothermia for 24 hours is currently underway.

NEUROCRITICAL CARE (2021)

Article Critical Care Medicine

Effect of intra-arrest trans-nasal evaporative cooling in out-of-hospital cardiac arrest: a pooled individual participant data analysis

Fabio Silvio Taccone et al.

Summary: In out-of-hospital cardiac arrest patients with initial shockable rhythms, intra-arrest cooling was associated with an increase in favorable neurological outcomes. However, no significant benefit was observed for the intervention in the entire population. Further studies are needed to confirm the potential benefits of this intervention in this subgroup of patients.

CRITICAL CARE (2021)

Article Critical Care Medicine

Rapid Induction of Therapeutic Hypothermia Using Transnasal High Flow Dry Air

Raghuram Chava et al.

THERAPEUTIC HYPOTHERMIA AND TEMPERATURE MANAGEMENT (2017)

Article Critical Care Medicine

Determinants of Effective Cooling During Endovascular Hypothermia

Patrick Lyden et al.

NEUROCRITICAL CARE (2012)

Article Critical Care Medicine

Brain temperature in volunteers subjected to intranasal cooling

L. Covaciu et al.

INTENSIVE CARE MEDICINE (2011)

Article Critical Care Medicine

Predictors and clinical implications of shivering during therapeutic normothermia

Neeraj Badjatia et al.

NEUROCRITICAL CARE (2007)